Breast Cancer Coverage from Every Angle

Aditya Bardia, MD, MPH, on Clinical Implications of New Findings on Elacestrant vs Standard-of-Care Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer

Posted: Saturday, December 10, 2022

Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses results from the EMERALD study, the emergence of the ESR1 mutation, and how it is involved in the development of resistance to endocrine therapy in previously treated patients. Dr. Bardia explains where elacestrant would fit in the overall treatment paradigm for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.